Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial

Kevin Kalinsky,Joseph A. Sparano,Xiaobo Zhong,Eleni Andreopoulou,Bret Taback,L. Wiechmann,Sheldon M. Feldman,Preya Ananthakrishnan,A. Ahmad,Serge Cremers,Anthony N. Sireci,J. R. Cross,Douglas Kanter Marks,P. Mundi,Eileen P. Connolly,Katherine D. Crew,Ma. Maurer,Hanina Hibshoosh,Shing Mirn Lee,Dawn L. Hershman

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial

2018

Introduction The PI3K/AKT/mTOR pathway is an oncogenic driver in breast cancer (BC). In this multi-center, pre-surgical study, we evaluated the tissue effects of the AKT inhibitor MK-2206 in women with stage I–III BC.

Keywords:

Cancer
PI3K/AKT/mTOR pathway
Breast cancer
General surgery
Protein kinase B
MK-2206
Medicine
in patient
Pathology
Biomarker (medicine)
Oncology
akt inhibitor
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations